Day: December 29, 2019

  1. Home
  2. Archives: December 2019

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial

Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial

Recent Posts

  • Prilenia enrolls first ALS patient in their Phase II / III study
  • Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
  • Prilenia shows positive effect on functional capacity in Huntigton’s Disease
  • Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
  • Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board